3- (4- (4- ((1- (2- chlorophenyl)ethoxy)carbonylamino)- 3- methyl- 5- isoxazolyl)benzylsulfanyl)propanoic acid methyl ester

Also Known As:

Ki16198

Networked: 2 relevant articles (1 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Isoxazoles: 155
      - 3-(4-(4-((1-(2-chlorophenyl)ethoxy)carbonylamino)-3-methyl-5-isoxazolyl)benzylsulfanyl)propanoic acid methyl ester: 2
Organic Chemicals: 133
- Carboxylic Acids: 973
  - Acyclic Acids
    - Propionates: 988
      - 3-(4-(4-((1-(2-chlorophenyl)ethoxy)carbonylamino)-3-methyl-5-isoxazolyl)benzylsulfanyl)propanoic acid methyl ester: 2
Lipids: 114793
- Fatty Acids: 27405
  - Volatile Fatty Acids: 3052
    - Propionates: 988
      - 3-(4-(4-((1-(2-chlorophenyl)ethoxy)carbonylamino)-3-methyl-5-isoxazolyl)benzylsulfanyl)propanoic acid methyl ester: 2

Experts

1.	Lin, Wei: 1 article (10/2016)
2.	Liu, Ben-Long: 1 article (10/2016)
3.	Pan, Hai-Li: 1 article (10/2016)
4.	Zhang, Yu-Qiu: 1 article (10/2016)
5.	Im, Dong-Soon: 1 article (06/2012)
6.	Ishii, Satoshi: 1 article (06/2012)
7.	Kimura, Takao: 1 article (06/2012)
8.	Komachi, Mayumi: 1 article (06/2012)
9.	Mogi, Chihiro: 1 article (06/2012)
10.	Ohta, Hideo: 1 article (06/2012)

Related Diseases

1.	Pancreatic Neoplasms (Pancreatic Cancer) 06/01/2012 - "In conclusion, Ki16198 is a promising orally active LPA antagonist for inhibiting the invasion and metastasis of pancreatic cancer cells. " 06/01/2012 - "Ki16198 inhibited LPA-induced migration and invasion in several pancreatic cancer cells in vitro, which was associated with the inhibition of LPA-induced MMP production. " 06/01/2012 - "Oral administration of Ki16198, which is effective for LPA(1) and LPA(3), into YAPC-PD pancreatic cancer cell-inoculated nude mice significantly inhibited tumor weight and remarkably attenuated invasion and metastasis to lung, liver, and brain, in association with inhibition of matrix metalloproteinase (MMP) accumulation in ascites in vivo. "
2.	Neoplasms (Cancer) 06/01/2012 - "Oral administration of Ki16198, which is effective for LPA(1) and LPA(3), into YAPC-PD pancreatic cancer cell-inoculated nude mice significantly inhibited tumor weight and remarkably attenuated invasion and metastasis to lung, liver, and brain, in association with inhibition of matrix metalloproteinase (MMP) accumulation in ascites in vivo. "
3.	Neoplasm Metastasis (Metastasis) 06/01/2012 - "In conclusion, Ki16198 is a promising orally active LPA antagonist for inhibiting the invasion and metastasis of pancreatic cancer cells. " 06/01/2012 - "Oral administration of Ki16198, which is effective for LPA(1) and LPA(3), into YAPC-PD pancreatic cancer cell-inoculated nude mice significantly inhibited tumor weight and remarkably attenuated invasion and metastasis to lung, liver, and brain, in association with inhibition of matrix metalloproteinase (MMP) accumulation in ascites in vivo. "
4.	Ascites 06/01/2012 - "Oral administration of Ki16198, which is effective for LPA(1) and LPA(3), into YAPC-PD pancreatic cancer cell-inoculated nude mice significantly inhibited tumor weight and remarkably attenuated invasion and metastasis to lung, liver, and brain, in association with inhibition of matrix metalloproteinase (MMP) accumulation in ascites in vivo. "
5.	Hyperalgesia 10/01/2016 - "We showed that the EDG2 antagonist Ki16198 blocked the mechanical allodynia induced by intrathecal LPA in naïve rats and attenuated mechanical allodynia in a rat model of bone cancer. "

Related Drugs and Biologics

1.	Matrix Metalloproteinases (MMPs)

Related Therapies and Procedures

1.	Oral Administration